Introduction
Angiotensin converting enzyme inhibitors are now widely used for the treatment of hypertension, and congestive cardiac failure. In general this group of drugs is well tolerated with few side effects or metabolic complications. The most common side effect is dry cough that is often worse at night, sometimes associated with a dry or sore throat. A husky voice or irritation in the throat are thought to be part of the same symptom cluster, probably with the same pathophysiology. The reported incidence of angiotensin converting enzyme inhibitor cough varies widely, with a frequency of up to 25% in one publication [1] .
As the importance of the renin angiotensin system in cardiovascular disease has emerged [2, 3] drugs targeting other components of the system are being evaluated, these include renin inhibitors, and angiotensin II receptor antagonists [4] . For a new inhibitor of the renin angiotensin system to be evaluated for cough tolerability, it should be compared in an equiefficacious dose to an angiotensin converting enzyme inhibitor. It is unlikely however, that in an efficacy study the incidence of cough would be high enough to make a comparison of different agents. These considerations necessitated a specific study to evaluate cough in patients shown to be sensitive to angiotensin converting enzyme inhibitors. Due to the low numbers of suitable patients, and the possibility of variability between those patients, a cross over design is optimal to increase the power of the study.
We report here a study to assess the reproducibility of cough and to compare its frequency with that of a novel inhibitor of the renin angiotensin system. 
Methods
Males and post-menopausal or surgically sterile females aged between 20 and 70 years, with a history of angiotensin converting enzyme inhibitor induced cough symptoms within the last 2 years gave written informed consent for the study. Patients with significant respiratory disease were excluded. The design was a double-blind, crossover comparison of two agents in five study periods. The study was conducted according to the guidelines of the Declaration of Helsinki, and ethical approval was obtained in all seven centres. Cough evaluation was performed by the physician based upon the symptoms reported by the patient at each clinic visit. It was defined as persisting dry cough, sore throat, husky voice or a tickling sensation or irritation in the throat, considered by the patient and physician to be similar to that experienced with previous angiotensin converting enzyme inhibitor treatment. Other possible causes of cough were excluded before assigning causality to the treatment.
In Period I patients were challenged with singleblind enalapril 20 mg daily for 1-4 weeks. Patients continued in the study if they experienced cough symptoms, of no other known cause, that had started after the treatment had begun. The only exception to this was in the case of those patients already experiencing cough symptoms at screening. Those patients who experienced cough symptoms entered Period II. This was a single-blind, 4 week placebo wash out period, during which time the cough had to resolve fully to allow the patient to be randomised. Period III was the first of the double-blind rechallenge periods. Patients were randomised to either enalapril 20 mg once daily or a renin inhibitor for up to 4 weeks. Those patients who experienced cough symptoms after at least 6 days' treatment were immediately switched to Period IV. If a patient did not experience any cough in Period III after 4 weeks, they then entered Period IV, which was a single-blind, 4 week placebo wash out period. In this period any induced cough had to resolve before entry into Period V. This was a further double-blind rechallenge period, in which patients were treated with the alternative active treatment for up to 4 weeks.
Patients who developed cough symptoms immediately discontinued the study, but were followed up Period I Period 11 Period III until symptom resolution. During the placebo periods, those patients whose cough symptoms did not resolve were also withdrawn. The overall study design is shown in Figure 1 .
Results
One hundred and seventeen patients were screened for the study, and 97 of these entered Period I. Nine patients dropped out due to non-development of cough, and 88 patients entered Period II. Ten patients withdrew at the end of Period II due to non-disappearance of cough and 64 patients were randomised into Period III. Mean age was 58.3 ± 6.6 years (±1 s.d.), 26 patients were male, and 91% were Caucasian. The distribution of patients in the subsequent periods is shown in Table 1 .
Of those patients in whom cough response could be assessed, 37 (62.7%) patients experienced cough symptoms while on enalapril (n = 59), and 16 (25.8%) while on the renin inhibitor (n = 62). The blood pressure data for this study are not presented as it was not verified due to the development of the renin inhibitor being terminated.
Adverse events (excluding cough) were similar in both groups with 23% of patients in each group reporting at least one event. 23% of patients reported adverse events during the placebo periods. No serious adverse events occurred during the study. The pattern of events is presented in Table 2 . Figure 1 Overall study design.
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Discussion
The pathophysiology of angiotensin converting enzyme inhibitor cough is unclear, but is a class effect thought to be related to the non-specificity of the pharmacological target, possibly due to the local accumulation of bradykinin, substance P, and prostaglandins. Other less well elucidated mediators may also be involved. These are thought to cause airway hyperreactivity [5] due to stimulation of unmyelinated C fibres [6] . Some support for this comes from the finding that amelioration of symptoms occurs with non-steroidal anti-inflammatory drugs, [7] and diuretics [8] (both of which affect prostaglandin biosynthesis), and in one report nifedipine [9] . Reports of the incidence of cough range from 0.5% [10] to 25% [3, 11] , the higher values occurring in studies that were prospectively designed to evaluate cough. Assessment is inevitably inaccurate [12] due to wide variation in reporting, and the denominator of number of patients prescribed the drug is not available. Although cough is a class effect of these drugs, a true difference in incidence between these compounds with a dose-response effect [13] could partly account for the large range in reported incidence.
A separate dose range finding study showed that the renin inhibitor was ineffective in treating hypertension, and as such no valid comparison between the tendency of the two drugs to produce cough can be made. However, the study design allowed assessment of the reproducibility of cough during the two enalapril treatment periods.
Of the 59 patients rechallenged with double-blind enalapril, only 37 (62.7%) experienced cough. The conditions of challenge were the same, with the exception of the blindedness in the later periods, suggesting that angiotensin converting enzyme inhibitor cough is not entirely reproducible.
When a causal relationship was established between angiotensin converting enzyme inhibitors and cough, the level of reports increased in proportion to the rate of prescriptions, and later showed a decline as the side effect became more expected [12] . In prospective studies (especially those with an open label design) there may be some over-reporting of cough due to observer bias, since cough symptoms are common. Clinical trials do not mimic clinical practice, and the more intensive questioning of a patient could lead to over-reporting of cough symptoms. This may have led to a positive selection bias during the first enalapril challenge, to account for the apparent lack of reproducibility. Duration of treatment is not a confounding factor in patients who were not on an angiotensin converting enzyme inhibitor at screening, as the cough had to appear within the 4 week enalapril challenge. In contrast, those patients on treatment and experiencing cough during the screening period, would have had longer for the symptoms to evolve. The relatively short rechallenge periods may then have been insufficient for the reappearance of cough. Twentyeight randomised patients were taking an angiotensin converting enzyme inhibitor at screening, but the duration of treatment was not recorded. It is likely to have been more than 4 weeks however, as the majority had an onset of cough more than 1 year previously. Of these patients two dropped out before receiving enalapril a second time, 15 (57.7%) experi-enced cough again, and 11 (42.3%) did not. This shows a slight trend for an increased incidence of cough with longer treatment, but is not significantly different from the study population as a whole.
Patients may experience the onset of cough symptoms after many months or years on therapy, sometimes after exposure to a viral upper respiratory tract infection. Trigger factors such as influenza [13] and rhinovirus infection [10, 14] may initiate the cough, and the presence of the angiotensin converting enzyme inhibitor may then maintain symptoms. With longer treatment, the greater is the chance of exposure to a trigger which may not have been repeated in the enalapril rechallenge.
Similarly, exposure in the single-blind challenge, but not subsequently in the double-blind rechallenge, might explain lack of reproducibility. This study was conducted in both northern and southern hemispheres, and encompassed winter in both areas. Exposure to viral pathogens is certain to have occurred, although non-angiotensin converting enzyme inhibitor cough symptoms prior to an active treatment period, excluded the patient. The lack of reproducibility in this study, if due to viral triggers, may suggest that a 'drug holiday' could resolve cough symptoms if the patient's disease allows for interruption of the angiotensin converting enzyme inhibitor.
It is unlikely that order of treatment played a part in the varying response as there was a 4 week placebo wash out between the active periods, and the cough must have fully resolved before entry into the next period. In those patients whose cough did not resolve during Period II, it is possible that slower clearance of the responsible mediators or different effects on tissue ACE, caused prolonged symptoms. This potentially may have biased the results by excluding patients who were more sensitive to cough. No patients dropped out for this reason during Period IV.
There is likely to be more than one population of patients reacting to multiple stimuli causing cough. Support comes from observations of differences in incidence by sex (more common in females), race, smoking habit [15] and angiotensin converting enzyme gene polymorphism [16, 17] . Furthermore, in some patients spontaneous resolution of cough occurs with uninterrupted treatment, without alteration of dose [18] , whereas in others cough may even worsen with up to 6 months' continued treatment [19] . An objective measure of cough sensitivity would reduce patient and observer variability. Several methods have been described using capsaicin [20, 21] as either a single inhalation or via a nebuliser, or citric acid provocation. These methods indicate that there is a reduction in the threshold for coughing in sensitive patients when treated with angiotensin converting enzyme inhibitors. In addition to symptom recording such approaches would increase the specificity and possibly the sensitivity of the diagnosis of cough symptoms.
This study has shown that even in a blinded trial with patients previously shown to have angiotensin converting enzyme inhibitor cough, the reproducibility is less than anticipated. Angiotensin converting enzyme inhibitors certainly promote the occurrence of cough, but other factors are also involved in initiating and maintaining the cough. With individual variability in susceptibility to symptoms, reproducibility is dependent upon factors other than treatment alone.
Assessment of cough is fraught with difficulty, particularly because of subjectivity and reporting bias. A more accurate measure of the incidence could employ an objective test together with symptom reporting. This could employ blinded observers and patients, with a test such as cough sensitivity to inhaled capsaicin. Local or systemic mediators, and the effect of physiological and pharmacological antagonists could then be assessed in an attempt to elucidate the mechanism. Better understanding of the mechanisms responsible for angiotensin converting enzyme inhibitor cough and its discomfort to the patient, may allow development of other inhibitors of the renin angiotensin system with improved tolerance.
